Navigation Links
Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
Date:11/25/2008

mbination with Idarubicin and Cytarabine in Patients with

Relapsed/Refractory AML

Session Name: Acute Myeloid Leukemia - Therapy, Excluding Transplantation

Session Date: Tuesday, December 9th, 2008 Presentation Time: 7:45 AM

Session Location: Moscone Center, Room 3020-3022-3024 - West

2008 ASH Annual Meeting - Poster Presentation

Title: Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense

Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients

with Relapsed/Refractory AML

Abstract: #1943, Poster Board # II-37

Session Date: Sunday, December 7th, 2008

Session Time: 6:00 PM - 8:00 PM

Session Location: Moscone Center, Hall A

About AEG35156

AEG35156, a second generation antisense which targets XIAP, is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy. Aegera's published data with AEG35156, both in vitro and in vivo, strongly supports this hypothesis, and validates XIAP as a novel oncology drug target. The activity of AEG35156 is currently being explored, in combination, or as a monotherapy, in the following indications: acute myeloid leukemia, non-small cell lung cancer, hepatocarcinoma, and chronic lymphocytic leukemia and indolent B-cell lymphomas. The latter study is being conducted with the financial and scientific support of the Leukemia and Lymphoma Society through their innovative Therapy Acceleration Program.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. In addition to AEG35156, Aegera has three additional programs in clinical development for the treatment of cancer and neuropathic pain. Details
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
2. Aegera Therapeutics welcomes two experienced executives to its board of directors
3. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
4. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
5. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
6. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
7. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
8. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
9. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
10. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
11. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...rta Centre for Advanced Micro Nano Technology Prod...r, , EDMONTON, Dec. 4 /PRNewswire/ - Today AC...ing how technologies like nanotechnology, biomater... the creation of innovative healthcare products th...st and outcomes of patient care, while opening new...
(Date:12/3/2009)...LLAS, Dec. 3 ACCESS PH..., today provided an update on its European commerc...r oral mucositis, a debilitating side effect of ra...ercially launched by Access, partner, SpePharm, in..., Italy, Norway, Greece and Sweden. Access is cond...
(Date:12/3/2009)...TON, Mass., Dec. 3 Calip... provider of tools and services for drug discovery...ng Image 4.0 software for IVIS® in vivo imagi...than 800 Caliper IVIS systems currently installed ...es advanced spectral unmixing tools to enhance flu...
(Date:12/2/2009)...EW YORK, Dec. 2 Reportlinker.com a...lable in its catalogue: ,, Carbondioxide Incub.../www.reportlinker.com/p0164368/Carbondioxide-Incub...ncubators are the most critical equipment used in ...r applications for providing a controlled environm...
Breaking Biology Technology:Alberta companies delivering new products to the health & medical marketplace 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Caliper Life Sciences Launches Living Image(R) 4.0 Software 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4
... Orchid Cellmark Inc.,(Nasdaq: ORCH ), a leading ...s, today announced a change in its sales and marke...as been appointed Vice President of North,America ...rporate,headquarters in Princeton New Jersey, Mr. ...hid,s North America business., Mr. Boschwitz brin...
...tistically Significant Improvement in Primary ...ontrol, SAN DIEGO, May 27 Favrille, Inc. (Nasdaq... Phase 3 registration trial,of Specifid(TM) follow...non-Hodgkin,s lymphoma (NHL)., (Logo: http://www... Analysis of time to progression (TTP), the primar...
... announces that the application,form for the 2008 ...idec,s,homepage. The winning application will be o...tion with Sidec. A Protein Tomography(TM) study is...o and will be funded by,Sidec., (Logo: http://ww...e Protein Tomography(TM) Award 2008 is given to ac...
Other Biology Technology:Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales 2Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales 3Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma 2Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma 3The Protein Tomography(TM) Award Now Published on Sidec's Homepage 2
(Date:12/4/2009)...rdens, Kew and the Natural History Museum believe ...idespread than previously thought, with many commo...way to being "meat eaters". A review paper, Murder...sights into vegetable carnivory, is published toda...he Linnean Society . , Carnivorous plants have c...
(Date:12/3/2009)...wswire-FirstCall/ -- BIO-key International, Inc. (...blic safety and finger-based biometric identificat...areholders at a Special Shareholder Meeting held t...ement Division to Interact911 Mobile Systems Inc. ...1.2% were opposed. ,, (Logo: http://www.newsco...
(Date:12/3/2009)...reliminary Press Conference Topics, Last Call! P...museum, Attention PIOs: Sending Press Releases t...on deadline 10 December, News Media registration...registration deadline THIS MONDAY, 7 December, W...rding visas for international reporters, please se...
Breaking Biology News(10 mins):Scientists think 'killer petunias' should join the ranks of carnivorous plants 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Amedisys Selects MetricStream for Integrated Enterprise wide GRC 61233 1Amedisys Selects MetricStream for Integrated Enterprise wide GRC 61233 2H1N1 Vaccinations Jam Phone Lines Increased Demand for TimeCenter Online Scheduling Software 61230 1H1N1 Vaccinations Jam Phone Lines Increased Demand for TimeCenter Online Scheduling Software 61230 2Zimmer Holdings Inc Announces Offering of Senior Notes 61227 1Zimmer Holdings Inc Announces Offering of Senior Notes 61227 2
...se of changes to the microbes that live in them ju...caused by global warming, according to scientists ...iety for General Microbiologys 162nd meeting being...ference Centre. , Tropical ecosystems are current... in coral reefs, which are made up of animals call...
...pausal women use hormone replacement therapy (HRT)...nopause. In a recent University of Missouri study,...n HRT, a synthetic progestin, could be a major fac...the researchers have compelling evidence that usin...tion in tumors, or a small molecular drug, known a...
...technology companies are focusing on the developme... of current diagnostic tests for cancer, reports G...o effectively move cancer therapy forward, a much ...e required, according to an article in the April 1.../chitem.aspx?aid=2428 ). , "Therapeutic protocol...
Other Biology News:Coral reefs and climate change: Microbes could be the key to coral death 2Coral reefs and climate change: Microbes could be the key to coral death 3MU researcher links hormone replacement therapy to breast cancer 2
Corning brand cover glass squares, 0.16 to 0.19mm thick from Sigma-Aldrich
...use in the Microsart e.motion are sterile-sealed, ... a specially designed individual package on a band...filter units ensures that they are perfectly flat ...ntees uniform dispensing of the individual membran...
Capillary Electrophoresis System from Agilent Technologies
Corning brand cover glass rectangles, 0.16 to 0.19mm thick from Sigma-Aldrich
Biology Products: